Agenda
Morning Session: Hepatitis C
4 AMA PRA Category 1 Credits™
We will review the virology, genotypes, modes of infection of HCV and characteristics of the clinical illness caused by acute and chronic infections. Birth-cohort screening plans for 2012 will be outlined. Tests for HCV, including PCR assays and genotyping, interpretations and indications for liver biopsies and complications of cirrhosis will all be discussed. We will show how to initiate and monitor patients during treatment with Telaprevir and Boceprevir, manage of side effects of rash and hematologic complications of therapy and deal with various patient populations including African Americans, HIV-coinfected and ESLD patients. New drugs in development including protease inhibitors, nucleoside/tide and no-nucleoside polymerase inhibitors, NS5A inhibitors, cyclophilin inhibitors and other novel agents will be discussed. We will outline what we think therapy of HCV will look like when all-oral regimens become available.
7:30 a.m.
Registration, Breakfast & View Exhibits
8 a.m.
Review of Viral Hepatitis, Discovery of HCV and Natural History
8:30 a.m.
Diagnostic Testing, Screening, Histology, Cirrhosis and Liver Biopsy
9 a.m.
Treatment Guidelines for Direct Acting Antivirals: Who, What, When and How
9:30 a.m.
DAAs for HIV-coinfected, ESLD and other Difficult-to-treat Populations
10 a.m.
Break & View Exhibits
10:20 a.m.
Combination and New Therapies in Development for HCV
Case Presentations, Discussion and Q&A
- Management of Side Effects of Therapy
- Treatment of Relapsers and Non-Responders
12:15 p.m.
Hep C Morning Session Adjournment
Afternoon Session: Hepatitis B
3.75 AMA PRA Category 1 Credits™
We will summarize the history and discovery of HBV infection, discuss the modes of infection and prevalence of disease, and differentiate between acute and chronic infections. We will discuss protective antibodies, vaccination, complications of cirrhosis and hepatocellular carcinoma, tests for HBV, including PCR assays, genotyping and mutation analysis. Update the latest results of trials with nucleoside and nucleotide analogues for the treatment of chronic HBV including entecavir, tenofovir pegylated interferon’s and combination regimens. We will include the latest AASLD guidelines for diagnosis, screening and treatment of chronic hepatitis B.
12:30 p.m.
Registration, Lunch & View Exhibits
1 p.m.
Discovery of HBV, Natural History, Vaccination and Prevention
1:30 p.m.
Diagnostic Testing, Liver Biopsy, Cirrhosis and Hepatocellular Carcinoma
2 p.m.
Nucleoside/Nucleotide Analogues & Pegylated Interferons for HBV
2:40 p.m.
Updated Data from AASLD 2011
3:10 p.m.
Break & View Exhibits
Case Presentations, Discussion and Q&A
- Management of Antiviral Resistance
- Treatment Algorithms and AASLD Guidelines
- HBeAg-Positive vs. HBeAg-Negative Patients
- Complications of Chronic Hepatitis B
5 p.m.
Hep B Afternoon Session Adjournment